Contrast-enhanced ultrasound (CEUS) is an emerging technology with no known nephrotoxicity. CEUS has been utilized in cardiac and abdominal imaging for decades in Asia and Europe and has recently received greater attention in the United States with its approval for characterization of indeterminate liver lesions. Emerging data suggest that CEUS has potential as a diagnostic imaging tool among individuals who have contraindications to CT and MRI. Few nephrologists are aware of CEUS and even fewer are aware of its potential applications among individuals with kidney disease. This review introduces CEUS to the nephrology community and provides a basic overview of CEUS technology. Knowledge of the applications, advantages, and disadvantages of CEUS provides the framework for nephrologists to make informed decisions regarding this emerging imaging test in appropriate circumstances. This review focuses on the use of CEUS for the characterization of indeterminate kidney lesions and summarizes the most recent data, some of which specifically includes patients with chronic kidney disease (CKD). The results demonstrate that CEUS has high sensitivity and moderate specificity for detecting malignancy in indeterminate kidney lesions among individuals with and without CKD. In conclusion, CEUS is an emerging imaging technique that may have clinically useful applications for detecting malignant kidney lesions, specifically in patients with CKD. However, most of the current data come from small, single-center studies, and larger, multicenter studies are needed.

Keywords:
Chronic kidney disease, Contrast media, Ultrasound
1.
Lowrance WT, Ordoñez J, Udaltsova N, Russo P, Go AS: CKD and the risk of incident cancer. J Am Soc Nephrol 2014; 25: 2327–2334.
2.
Faubel S, Patel NU, Lockhart ME, Cadnapaphornchai MA: Renal relevant radiology: use of ultrasonography in patients with AKI. Clin J Am Soc Nephrol 2014; 9: 382–394.
3.
Maya ID, Maddela P, Barker J, Allon M: Percutaneous renal biopsy: comparison of blind and real-time ultrasound-guided technique. Semin Dial 2007; 20: 355–358.
4.
Filocamo MT, Zanazzi M, Li Marzi V, Guidoni L, Villari D, Dattolo E, Nicita G: Renal cell carcinoma of native kidney after renal transplantation: clinical relevance of early detection. Transplant Proc 2009; 41: 4197–4201.
5.
Frascà GM, Sandrini S, Cosmai L, Porta C, Asch W, Santoni M, Salviani C, D'Errico A, Malvi D, Balestra E, Gallieni M: Renal cancer in kidney transplanted patients. J Nephrol 2015; 28: 659–668.
6.
McDonald JS, McDonald RJ, Carter RE, Katzberg RW, Kallmes DF, Williamson EE: Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate. Radiology 2014; 271: 65–73.
7.
Wilhelm-Leen E, Montez-Rath ME, Chertow G: Estimating the Risk of Radiocontrast-Associated Nephropathy. J Am Soc Nephrol 2017; 28: 653–659.
8.
Hinson JS, Ehmann MR, Fine DM, Fishman EK, Toerper MF, Rothman RE, Klein EY: Risk of acute kidney injury after intravenous contrast media administration. Ann Emerg Med 2017; 69: 577–586.e574.
9.
Grobner T: Gadolinium–a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104–1108.
10.
Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS: Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359–2362.
11.
Becker S, Walter S, Witzke O, Kreuter A, Kribben A, Mitchell A: Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis. Nephron Clin Pract 2012; 121:c91–c94.
12.
Soulez G, Bloomgarden DC, Rofsky NM, Smith MP, Abujudeh HH, Morgan DE, Lichtenstein RJ, Schiebler ML, Wippold FJ 2nd, Russo C, Kuhn MJ, Mennitt KW, Maki JH, Stolpen A, Liou J, Semelka RC, Kirchin MA, Shen N, Pirovano G, Spinazzi A: Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3–5 chronic kidney disease undergoing MRI with injected gadobenate dimeglumine or gadoteridol. AJR Am J Roentgenol 2015; 205: 469–478.
13.
Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, Haruyama T, Kitajima K, Furui S: Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015: 276: 228–232.
14.
McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, Williamson EE, Eckel LJ: Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology 2015: 275: 772–782.
15.
Olchowy C, Cebulski K, Łasecki M, Chaber R, Olchowy A, Kalwak K, Zaleska-Dorobisz U: The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity – a systematic review. PLoS One 2017; 12: e0171704.
16.
Cao Y, Zhang Y, Shih G, Zhang Y, Bohmart A, Hecht EM, Prince MR: Effect of renal function on gadolinium-related signal increases on unenhanced T1-weighted brain magnetic resonance imaging. Invest Radiol 2016; 51: 677–682.
17.
ACR, Appropriateness Criteria Indeterminate Renal Mass, 2014.
18.
Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC: Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults. AJR Am J Roentgenol 2007; 189: 1533–1538.
19.
Piscaglia F, Nolsøe C, Dietrich CF, Cosgrove DO, Gilja OH, Bachmann Nielsen M, Albrecht T, Barozzi L, Bertolotto M, Catalano O, Claudon M, Clevert DA, Correas JM, D'Onofrio M, Drudi FM, Eyding J, Giovannini M, Hocke M, Ignee A, Jung EM, Klauser AS, Lassau N, Leen E, Mathis G, Saftoiu A, Seidel G, Sidhu PS, ter Haar G, Timmerman D, Weskott HP: The EFSUMB guidelines and recommendations on the clinical practice of contrast enhanced ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall Med 2012; 33: 33–59.
20.
Piscaglia F, Bolondi L; Italian Society for Ultrasound in Medicine and Biology (SIUMB) Study Group on Ultrasound Contrast Agents: The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol 2006; 32: 1369–1375.
21.
Main ML, Goldman JH, Grayburn PA: Thinking outside the “box”-the ultrasound contrast controversy. J Am Coll Cardiol 2007; 50: 2434–2437.
22.
Main ML, Ryan AC, Davis TE, Albano MP, Kusnetzky LL, Hibberd M: Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). Am J Cardiol 2008; 102: 1742–1746.
23.
Wei K, Mulvagh SL, Carson L, Davidoff R, Gabriel R, Grimm RA, Wilson S, Fane L, Herzog CA, Zoghbi WA, Taylor R, Farrar M, Chaudhry FA, Porter TR, Irani W, Lang RM: The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. J Am Soc Echocardiogr 2008; 21: 1202–1206.
24.
Main ML, Hibberd MG, Ryan A, Lowe TJ, Miller P, Bhat G: Acute mortality in critically ill patients undergoing echocardiography with or without an ultrasound contrast agent. JACC Cardiovasc Imaging 2014; 7: 40–48.
25.
Wever-Pinzon O, Suma V, Ahuja A, Romero J, Sareen N, Henry SA, De Benedetti Zunino M, Chaudhry FF, Suryadevara RS, Sherrid MV, Chaudhry FA: Safety of echocardiographic contrast in hospitalized patients with pulmonary hypertension: a multi-center study. Eur Heart J Cardiovasc Imaging 2012; 13: 857–862.
26.
Kalra A, Shroff GR, Herzog CA: Safety of ultrasound contrast agents in patients with intracardiac shunts. J Am Soc Echocardiogr 2014; 27: 1359.
27.
Platts DG, Luis SA, Roper D, Burstow D, Call T, Forshaw A, Pascoe R: The safety profile of perflutren microsphere contrast echocardiography during rest and stress imaging: results from an Australian multicentre cohort. Heart Lung Circ 2013; 22: 996–1002.
28.
Miller DL, Dou C, Wiggins RC: Glomerular capillary hemorrhage induced in rats by diagnostic ultrasound with gas-body contrast agent produces intratubular obstruction. Ultrasound Med Biol 2009; 35: 869–877.
29.
Miller DL, Dou C, Wiggins RC: Contrast-enhanced diagnostic ultrasound causes renal tissue damage in a porcine model. J Ultrasound Med 2010; 29: 1391–1401.
30.
Miller DL, Averkiou MA, Brayman AA, Everbach EC, Holland CK, Wible JH Jr, Wu J: Bioeffects considerations for diagnostic ultrasound contrast agents. J Ultrasound Med 2008; 27: 611–632; quiz 633–616.
31.
Paefgen V, Doleschel D, Kiessling F: Evolution of contrast agents for ultrasound imaging and ultrasound-mediated drug delivery. Front Pharmacol 2015; 6: 197.
32.
Appis AW, Tracy MJ, Feinstein SB: Update on the safety and efficacy of commercial ultrasound contrast agents in cardiac applications. Echo Res Pract 2015; 2:R55–R62.
33.
D'Onofrio M, Crosara S, De Robertis R, Canestrini S, Mucelli RP: Contrast-enhanced ultrasound of focal liver lesions. AJR Am J Roentgenol 2015; 205:W56–W66.
34.
Bhayana D, Kim TK, Jang HJ, Burns PN, Wilson SR: Hypervascular liver masses on contrast-enhanced ultrasound: the importance of washout. AJR Am J Roentgenol 2010; 194: 977–983.
35.
Kono Y, Lyshchik A, Cosgrove D, Dietrich CF, Jang HJ, Kim TK, Piscaglia F, Willmann JK, Wilson SR, Santillan C, Kambadakone A, Mitchell D, Vezeridis A, Sirlin CB: Contrast enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS ®): the official version by the American College of radiology (ACR). Ultraschall Med 2017; 38: 85–86.
36.
Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsoe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX: Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver – update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med 2013; 34: 11–29.
37.
Barr RG: How to develop a contrast-enhanced ultrasound program. J Ultrasound Med 2017; 36: 1225–1240.
38.
Giordano M, Marzolla R, Puteo F, Scianaro L, Caringella DA, Depalo T: Voiding urosonography as first step in the diagnosis of vesicoureteral reflux in children: a clinical experience. Pediatr Radiol 2007; 37: 674–677.
39.
Chang EH, Chong WK, Kasoji S, Dayton PA, Rathmell WK: Management of indeterminate cystic kidney lesions: review of contrasteEnhanced ultrasound as a diagnostic tool. Urology 2015; 87: 1–10.
40.
Sawhney S, Wilson SR: Can ultrasound with contrast enhancement replace nonenhanced computed tomography scans in patients with contraindication to computed tomography contrast agents? Ultrasound Q 2017; 33: 125–132.
41.
Girometti R, Stocca T, Serena E, Granata A, Bertolotto M: Impact of contrast-enhanced ultrasound in patients with renal function impairment. World J Radiol 2017; 9: 10–16.
42.
Zarzour JG, Lockhart ME, West J, Turner E, Jackson BE, Thomas JV, Robbin ML: Contrast-enhanced ultrasound classification of previously indeterminate renal lesions. J Ultrasound Med 2017; 36: 1819–1827.
43.
Defortescu G, Cornu JN, Bejar S, Giwerc A, Gobet F, Werquin C, Pfister C, Nouhaud FX: Diagnostic performance of contrast-enhanced ultrasonography and magnetic resonance imaging for the assessment of complex renal cysts: a prospective study. Int J Urol 2017; 24: 184–189.
44.
Sanz E, Hevia V, Gomez V, Alvarez S, Fabuel JJ, Martinez L, Rodriguez-Patron R, Gonzalez-Gordaliza C, Burgos FJ: Renal complex cystic masses: usefulness of contrast-enhanced ultrasound (CEUS) in their assessment and Its agreement with computed tomography. Curr Urol Rep 2016; 17: 89.
45.
Chang EH, Chong WK, Kasoji SK, Fielding JR, Altun E, Mullin LB, Kim JI, Fine JP, Dayton PA, Rathmell WK: Diagnostic accuracy of contrast-enhanced ultrasound for characterization of kidney lesions in patients with and without chronic kidney disease. BMC Nephrol 2017; 18: 266.
46.
Ascenti G, Mazziotti S, Zimbaro G, Settineri N, Magno C, Melloni D, Caruso R, Scribano E: Complex cystic renal masses: characterization with contrast-enhanced US. Radiology 2007; 243: 158–165.
47.
Clevert DA, Minaifar N, Weckbach S, Jung EM, Stock K, Reiser M, Staehler M: Multislice computed tomography versus contrast-enhanced ultrasound in evaluation of complex cystic renal masses using the Bosniak classification system. Clini Hemorheol Microcirc 2008; 39: 171–178.
48.
Quaia E, Bertolotto M, Cioffi V, Rossi A, Baratella E, Pizzolato R, Cov MA: Comparison of contrast-enhanced sonography with unenhanced sonography and contrast-enhanced CT in the diagnosis of malignancy in complex cystic renal masses. AJR Am J Roentgenol 2008; 191: 1239–1249.
49.
Park BK, Kim B, Kim SH, Ko K, Lee HM, Choi HY: Assessment of cystic renal masses based on Bosniak classification: comparison of CT and contrast-enhanced US. Eur J Radiol 2007; 61: 310–314.
50.
Barr RG, Peterson C, Hindi A: Evaluation of indeterminate renal masses with contrast-enhanced US: a diagnostic performance study. Radiology 2014; 271: 133–142.
51.
Alzaraa A, Gravante G, Chung WY, Al-Leswas D, Bruno M, Dennison AR, Lloyd DM: Targeted microbubbles in the experimental and clinical setting. Am J Surg 2012; 204: 355–366.
52.
Baron Toaldo M, Salvatore V, Marinelli S, Palama C, Milazzo M, Croci L, Venerandi L, Cipone M, Bolondi L, Piscaglia F: Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma. Mol Imaging Biol 2015; 17: 29–37.
53.
Gao Y, Hernandez C, Yuan HX, Lilly J, Kota P, Zhou H, Wu H, Exner AA: Ultrasound molecular imaging of ovarian cancer with CA-125 targeted nanobubble contrast agents. Nanomedicine 2017; 13: 2159–2168.
54.
Eschbach RS, Clevert DA, Hirner-Eppeneder H, Ingrisch M, Moser M, Schuster J, Tadros D, Schneider M, Kazmierczak PM, Reiser M, Cyran CC: Contrast-enhanced ultrasound with VEGFR2-targeted microbubbles for monitoring regorafenib therapy effects in experimental colorectal adenocarcinomas in rats with DCE-MRI and immunohistochemical validation. PLoS One 2017; 12:e0169323.
55.
Lindner JR, Song J, Christiansen J, Klibanov AL, Xu F, Ley K: Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation 2001; 104: 2107–2112.
56.
Deshpande N, Lutz AM, Ren Y, Foygel K, Tian L, Schneider M, Pai R, Pasricha PJ, Willmann JK: Quantification and monitoring of inflammation in murine inflammatory bowel disease with targeted contrast-enhanced US. Radiology 2012; 262: 172–180.
57.
Yang H, Xiong X, Zhang L, Wu C, Liu Y: Adhesion of bio-functionalized ultrasound microbubbles to endothelial cells by targeting to vascular cell adhesion molecule-1 under shear flow. Int J Nanomedicine 2011; 6: 2043–2051.
58.
Kaufmann BA, Sanders JM, Davis C, Xie A, Aldred P, Sarembock IJ, Lindner JR: Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation 2007; 116: 276–284.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.